Users should be aware of potential risks and quality variability in compounded GLP-1 and GIP agonists.

“Have never tried it, but it seems the issue many have is with the source not the peptide itself.”

“the concerning part about the gp1s is uh to me is what we're starting to they've been able to be compounded because there was a uh shortage and the way it works with compounding pharmacy is because those are brand named drugs and they're not patented for the peptide right they're patented for the delivery system which is the pen — which most people don't realize and they've been able to be compounded and then way more affordable because they're compounded — and there is rumors that the pharmaceutical companies now have Supply back they'll come back and they will you know remove the ability to to allow these peptides to be compounded which means we'll have to stick to traditional dosages and people will lose access because they're going to be way more expensive”

“but seems rampant today is the use of compounding phies to formulate these and we're going to do a a bit of a double click on that because um people who have listened to the podcast are no doubt familiar with what compounding pharmacies are and we covered that on a previous AMA um we obviously uh a point to make sure people understand The Good the Bad and the Ugly of compounding pharmacies I certainly don't want to sit here and say that compounding pharmacies are bad but you have to you know there's a bit of a buyer beware and they're not all created equal”